Gout Management

Introduction to Gout Management

Gout management involves a combination of lifestyle modifications and pharmacological interventions, with guidelines provided by the American College of Rheumatology and European League Against Rheumatism (EULAR) 1, 2, 3, 4

The European League Against Rheumatism (EULAR) recommends colchicine 0.5-1 mg daily for gout prophylaxis, with higher doses leading to more side effects, particularly gastrointestinal issues 5, 6
NSAIDs should be used with gastric protection if indicated, as recommended by the European League Against Rheumatism (EULAR) 5
Colchicine and naproxen effectively reduce the risk of acute gout attacks during initiation of urate-lowering therapy, with colchicine associated with more diarrhea (8.4% vs. 2.7% with naproxen) and naproxen associated with more gastrointestinal and abdominal pain (3.2% vs. 1.2% with colchicine) 6
First-line treatment options for acute gout flares include colchicine (1.2 mg at first sign of flare followed by 0.6 mg one hour later), NSAIDs (such as naproxen 500 mg twice daily), or glucocorticoids (oral, intraarticular, or intramuscular), as recommended by the American College of Rheumatology 4
Full anti-inflammatory doses of NSAIDs, such as naproxen 500 mg twice daily or indomethacin 50 mg three times daily, are an effective alternative to colchicine, but should be used with caution in patients with cardiovascular disease, heart failure, or renal impairment 4
Corticosteroids, such as oral prednisone/prednisolone 35 mg daily for 5 days, are as effective as NSAIDs with potentially fewer adverse effects, particularly useful in patients with contraindications to colchicine or NSAIDs, as recommended by the American College of Physicians 7, 4

ULT should be considered for patients with frequent gout flares (>2/year), tophaceous gout, radiographic damage due to gout, CKD stage >3, or serum urate >9 mg/dL, as recommended by the American College of Rheumatology 4
Allopurinol is the preferred first-line ULT, starting at ≤100 mg/day (lower in CKD) with gradual dose titration to achieve serum urate target of <6 mg/dL, as recommended by the American College of Rheumatology 4
Long-term ULT should be considered for patients with radiographic damage attributable to gout, frequent gout flares (>2/year), presence of tophi, CKD stage >3, serum urate >9 mg/dl, or urolithiasis, with first-line ULT being allopurinol, starting at ≤100 mg/day with gradual dose titration, as recommended by the American College of Rheumatology 8, 9, 4

Low-dose colchicine (0.6 mg once or twice daily) or low-dose NSAIDs may be used for prophylaxis, with the American College of Rheumatology recommending these options for patients at risk of flares 4
Prophylactic therapy with low-dose colchicine (0.6 mg once or twice daily) or low-dose NSAIDs should be considered when starting urate-lowering treatment (ULT), and continued for 3-6 months after starting ULT, as recommended by the American College of Rheumatology and European League Against Rheumatism (EULAR) guidelines 1, 7, 2, 4
Lifestyle modifications, including weight loss, limiting alcohol consumption, reducing intake of purine-rich foods, avoiding high-fructose corn syrup and sugary beverages, and staying well hydrated, can help manage gout symptoms, as recommended by the American Heart Association and European League Against Rheumatism (EULAR) guidelines 1, 3

Gout management in diabetic patients requires consideration of renal function, cardiovascular risk, and other comorbidities, with guidelines provided by the American College of Rheumatology and European League Against Rheumatism (EULAR) 1, 2, 3
For mild-moderate renal impairment (CrCl 30-80 mL/min), standard colchicine dosing with monitoring is recommended, while for severe renal impairment (CrCl <30 mL/min), colchicine and NSAIDs should be avoided, and corticosteroids should be used instead, as recommended by the American College of Rheumatology and European League Against Rheumatism (EULAR) guidelines 3, 4

Schedule follow-up appointment in 1-2 weeks to discuss potential long-term urate-lowering therapy (ULT) and monitor serum uric acid levels, as recommended by the American College of Rheumatology and European League Against Rheumatism (EULAR) guidelines 2
Urate-lowering therapy should not be interrupted during acute flares, and prophylaxis should be initiated when starting urate-lowering therapy to prevent flares, with options including low-dose colchicine (0.6 mg once or twice daily) or low-dose NSAIDs for up to 6 months, as recommended by the American College of Rheumatology and European League Against Rheumatism (EULAR) guidelines 4, 2